| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Alejandro Madrigal | Q5665197 |
| P2093 | author name string | Aurore Saudemont | |
| Anushruti Sarvaria | |||
| P2860 | cites work | Specific suppression of delayed hypersensitivity: the possible presence of a suppressor B cell in the regulation of delayed hypersensitivity. | Q54003794 |
| Intratumoral Cytokines and Tumor Cell Biology Determine Spontaneous Breast Cancer-Specific Immune Responses and Their Correlation to Prognosis | Q57270774 | ||
| Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine | Q64376751 | ||
| Natural resistance mechanisms may play a role in protection against chemical carcinogenesis | Q72121067 | ||
| Feedback suppression of the immune response in vivo. I. Immune B cells induce antigen-specific suppressor T cells | Q72755744 | ||
| Feedback suppression of the immune response in vivo. III. Lyt-1+ B cells are suppressor-inducer cells | Q72804545 | ||
| B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion | Q73343324 | ||
| Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation | Q77704355 | ||
| Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides | Q81377964 | ||
| A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years | Q81459935 | ||
| Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer | Q81774016 | ||
| Increased percentage of B cells in patients with more advanced hepatocellular carcinoma | Q84696385 | ||
| RETRACTED: Aberrant frequency of IL-10-producing B cells and its association with Treg and MDSC cells in Non Small Cell Lung Carcinoma patients | Q86610664 | ||
| Cancer immunoediting from immune surveillance to immune escape | Q24655415 | ||
| Suppression, subversion and escape: the role of regulatory T cells in cancer progression | Q27026151 | ||
| Immunity, Inflammation, and Cancer | Q27861048 | ||
| Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression | Q29615344 | ||
| Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs | Q31158755 | ||
| B10 cell regulation of health and disease | Q33726933 | ||
| Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice | Q34083166 | ||
| CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients | Q34093165 | ||
| Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses | Q34111836 | ||
| Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. | Q34144779 | ||
| B cells regulate autoimmunity by provision of IL-10. | Q34150590 | ||
| Prevention of arthritis by interleukin 10-producing B cells | Q34178104 | ||
| B-cell suppression of delayed hypersensitivity reactions | Q34211944 | ||
| Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD | Q34292984 | ||
| Peripheral development of B cells in mouse and man. | Q34298533 | ||
| IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses | Q34330562 | ||
| B-cell biology and development | Q34331269 | ||
| Multifunctional role of dextran sulfate sodium for in vivo modeling of intestinal diseases | Q34361820 | ||
| Regulatory B cells: origin, phenotype, and function. | Q34473148 | ||
| Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. | Q34495557 | ||
| Novel suppressive function of transitional 2 B cells in experimental arthritis | Q34634297 | ||
| IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases | Q34658996 | ||
| B cells promote tumor progression via STAT3 regulated-angiogenesis | Q34755398 | ||
| A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses | Q34778834 | ||
| B lymphocytes: how they develop and function. | Q34813171 | ||
| FcRgamma activation regulates inflammation-associated squamous carcinogenesis. | Q34859537 | ||
| Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells | Q34987934 | ||
| A granulocyte-macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. | Q34996561 | ||
| B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis | Q35081453 | ||
| Beta-catenin signaling drives differentiation and proinflammatory function of IRF8-dependent dendritic cells | Q35097001 | ||
| Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice | Q35187089 | ||
| Immunological enhancement of tumor homografts in mice: a review. | Q35271130 | ||
| Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. | Q35484992 | ||
| Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo | Q35685566 | ||
| Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy | Q35849866 | ||
| Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells | Q36081961 | ||
| Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. | Q36085011 | ||
| IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection | Q36345904 | ||
| B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation | Q36368717 | ||
| Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. | Q36385029 | ||
| CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer | Q36545192 | ||
| Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α. | Q36675315 | ||
| Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. | Q36745357 | ||
| Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer | Q36769318 | ||
| Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8⁺ T cell function in vitro. | Q36775406 | ||
| CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer | Q36832883 | ||
| Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. | Q36835221 | ||
| Peripheral B cell subsets | Q36867717 | ||
| B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice | Q37069120 | ||
| The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals | Q37069155 | ||
| In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy | Q37086932 | ||
| Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-γ+CD4+ T cell numbers during colitis development in mice | Q37163714 | ||
| Human marginal zone B cells. | Q37419372 | ||
| B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer | Q37690373 | ||
| Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu | Q37737802 | ||
| B-lymphocyte biology | Q37781385 | ||
| B cells and their mediators as targets for therapy in solid tumors | Q38090232 | ||
| Antibody-independent functions of B cells: a focus on cytokines | Q38525103 | ||
| PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression. | Q38790070 | ||
| CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells | Q38814703 | ||
| Glioma cell-derived placental growth factor induces regulatory B cells | Q38934778 | ||
| Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway | Q38949223 | ||
| Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg). | Q39281335 | ||
| Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients | Q40241255 | ||
| B-cell-derived lymphotoxin promotes castration-resistant prostate cancer | Q40440899 | ||
| Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses | Q40982736 | ||
| IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation | Q41049735 | ||
| PD-L1hi B cells are critical regulators of humoral immunity. | Q41529474 | ||
| Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation | Q41718326 | ||
| Transcriptomics Identify CD9 as a Marker of Murine IL-10-Competent Regulatory B Cells | Q41856533 | ||
| Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice | Q42721429 | ||
| B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. | Q42742024 | ||
| B cell-regulated immune responses in tumor models and cancer patients | Q42969728 | ||
| Clinical significance of regulatory B cells in the peripheral blood of patients with oesophageal cancer | Q43184060 | ||
| CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation | Q43406136 | ||
| B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion | Q43418649 | ||
| Inhibitory effects of B cells on antitumor immunity. | Q44423014 | ||
| B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. | Q44945891 | ||
| Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells | Q44996678 | ||
| De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent | Q46068963 | ||
| Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation | Q47231928 | ||
| Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma | Q47324803 | ||
| CD24(hi)CD27⁺ and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. | Q50757178 | ||
| Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission. | Q50786110 | ||
| CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. | Q50955882 | ||
| Marginal zone B cells regulate antigen-specific T cell responses during infection. | Q50962313 | ||
| IL‐10 produced by activated human B cells regulates CD4+ T‐cell activation in vitro | Q51038853 | ||
| Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. | Q53200046 | ||
| Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. | Q53256514 | ||
| NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. | Q53257187 | ||
| Tumor-associated immunoglobulins. Enhancement of syngeneic tumors by IgG2-containing tumor eluates. | Q53603883 | ||
| B cells inhibit induction of T cell-dependent tumor immunity. | Q53682449 | ||
| Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. | Q53855919 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neoplasm | Q1216998 |
| B-lymphocyte subsets | Q70069855 | ||
| regulatory B cell | Q18393925 | ||
| P1104 | number of pages | 13 | |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 662-674 | |
| P577 | publication date | 2017-06-19 | |
| 2017-08-01 | |||
| P1433 | published in | Cellular and Molecular Immunology | Q26842256 |
| P1476 | title | B cell regulation in cancer and anti-tumor immunity | |
| P478 | volume | 14 |
| Q58698491 | A Paradoxical Correlation of Cancer-Associated Fibroblasts With Survival Outcomes in B-Cell Lymphomas and Carcinomas |
| Q54960920 | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. |
| Q92716156 | Antitumoral and Immunomodulatory Effect of Mahonia aquifolium Extracts |
| Q93081293 | B Cells as an Immune-Regulatory Signature in Ovarian Cancer |
| Q92669559 | B cells and tertiary lymphoid structures promote immunotherapy response |
| Q92978709 | B cells, plasma cells and antibody repertoires in the tumour microenvironment |
| Q90399644 | Biology and Therapeutic Targets of Colorectal Serrated Adenocarcinoma; Clues for a Histologically Based Treatment against an Aggressive Tumor |
| Q92922157 | Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments |
| Q60938527 | Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma |
| Q93162228 | Cancer stemness, intratumoral heterogeneity, and immune response across cancers |
| Q89538337 | Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients |
| Q90415589 | Characterization of intratumoral and circulating IL-10-producing B cells in gastric cancer |
| Q91648168 | Circulating exosomes from esophageal squamous cell carcinoma mediate the generation of B10 and PD-1high Breg cells |
| Q57062487 | Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor |
| Q89764835 | Distribution of BCG-CWS-Loaded Nanoparticles in the Spleen After Intravenous Injection Affects Cytotoxic T Lymphocyte Activity |
| Q90708034 | Double-edge Role of B Cells in Tumor Immunity: Potential Molecular Mechanism |
| Q91305716 | Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non-small-cell Lung Cancer |
| Q59795167 | Emerging Role of Immunosuppression in Diseases Induced by Micro- and Nano-Particles: Time to Revisit the Exclusive Inflammatory Scenario |
| Q90019854 | Follicular cytotoxic CD8 T cells present high cytokine expression, and are more susceptible to Breg-mediated suppression in non-small cell lung cancer |
| Q91178543 | Germline variants associated with leukocyte genes predict tumor recurrence in breast cancer patients |
| Q55364617 | Growth and Immune Evasion of Lymph Node Metastasis. |
| Q98174930 | Hyperthermic intraperitoneal chemotherapy (HIPEC): Should we look closer at the microenvironment? |
| Q91317402 | IL-10-producing B cells in differentiated thyroid cancer suppress the effector function of T cells but improve their survival upon activation |
| Q55031605 | IL-35-producing B cells in gastric cancer patients. |
| Q58084858 | Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq |
| Q91178274 | If we build it they will come: targeting the immune response to breast cancer |
| Q92800268 | Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study |
| Q89556686 | Immune crosstalk in cancer progression and metastatic spread: a complex conversation |
| Q58561592 | Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression |
| Q55652343 | Immunotherapy for Gastric Cancer: Time for a Personalized Approach? |
| Q52641718 | Induction of human dendritic cell maturation by naïve and memory B-cell subsets requires different activation stimuli. |
| Q47350877 | JQ1, a BET inhibitor, controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF-κB axis |
| Q57791800 | Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis |
| Q93364905 | MiR-15a/16-1 deficiency induces IL-10-producing CD19+ TIM-1+ cells in tumor microenvironment |
| Q90481747 | Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies |
| Q92406903 | Molecular classification of IDH-mutant glioblastomas based on gene expression profiles |
| Q93052035 | Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies |
| Q92734194 | New insights into the significance of the BCR repertoire in B-1 cell development and function |
| Q102379531 | Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer |
| Q88911071 | Post-transcriptional regulator Rbm47 elevates IL-10 production and promotes the immunosuppression of B cells |
| Q54257360 | Potential Role for Regulatory B Cells as a Major Source of Interleukin-10 in Spleen from Plasmodium chabaudi-Infected Mice. |
| Q92727496 | Prediagnostic Immune Cell Profiles and Breast Cancer |
| Q102075398 | Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C virus |
| Q58555322 | Regulatory B and T lymphocytes in multiple sclerosis: friends or foes? |
| Q55030441 | Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. |
| Q59335796 | Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology |
| Q64069937 | TLR3 Activation of Intratumoral CD103 Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity |
| Q92656858 | Targeting immune cells for cancer therapy |
| Q64921356 | The B-side of Cancer Immunity: The Underrated Tune. |
| Q58749956 | The Role of Allograft Inflammatory Factor-1 in the Effects of Experimental Diabetes on B Cell Functions in the Heart |
| Q64253571 | The Role of the Immune System in Cutaneous Squamous Cell Carcinoma |
| Q90452290 | The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy |
| Q96952246 | The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications |
| Q98205361 | The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy |
| Q92417123 | The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer |
| Q96348548 | The tumor immune microenvironmental analysis of 2,033 transcriptomes across 7 cancer types |
| Q49592937 | Tumor Immuno-Environment in Cancer Progression and Therapy |
| Q52328709 | Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. |
| Q89981018 | Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy |
| Q57806419 | Unstimulated Adult Human B Cells Include an IL-10+ Population with Suppressive Properties and an Activated Phenotype |
| Q87944215 | [B cells in head and neck oncology] |
| Q55312964 | β-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion. |
Search more.